- Home
- CCK vs BMRN Comparison
CCK vs BMRN Comparison
Compare CCK & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCK | BMRN |
|---|---|---|
| Founded | 1906 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.5B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CCK | BMRN |
|---|---|---|
| Price | $101.25 | $52.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 19 |
| Target Price | ★ $118.57 | $88.42 |
| AVG Volume (30 Days) | 2.1M | ★ 2.9M |
| Earning Date | 02-04-2026 | 10-27-2025 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | ★ 888.69 | 59.53 |
| EPS | ★ 8.10 | 2.68 |
| Revenue | ★ $12,141,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | $4.78 | $13.39 |
| Revenue Next Year | $2.75 | $7.57 |
| P/E Ratio | ★ $12.08 | $19.89 |
| Revenue Growth | 3.27 | ★ 12.39 |
| 52 Week Low | $75.98 | $50.76 |
| 52 Week High | $109.48 | $73.51 |
Technical Indicators
Market Signals| Indicator | CCK | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 62.29 | 40.55 |
| Support Level | $93.48 | $52.55 |
| Resistance Level | $100.12 | $54.33 |
| Average True Range (ATR) | 1.90 | 1.27 |
| MACD | 0.22 | -0.23 |
| Stochastic Oscillator | 99.19 | 23.42 |
Price Performance
Historical ComparisonAbout CCK Crown Holdings Inc.
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.